Axcella Health is a clinical-stage biotechnology company that is revolutionizing the treatment of complex diseases. They specialize in developing endogenous metabolic modulator (EMM) compositions, which have the unique ability to impact and regulate metabolism, controlling various biological functions. By combining their deep understanding of biological pathways with advancements in systems biology and machine learning, they have created multi-targeted EMM compositions with the potential to address the unmet medical needs of patients with a range of complex conditions.

Led by an accomplished team of leaders, including President & CEO Bill Hinshaw and Chief Medical Officer Margaret Koziel, Axcella Health is committed to unlocking the full potential of EMMs. With a strong emphasis on ownership, they pride themselves on their innovative approach to healthcare. Through their groundbreaking research and advancements in the field, Axcella Health is poised to make significant contributions to the field of biotechnology and improve the lives of patients worldwide